AusBiotech

Osteopore secures US distribution agreement for government facilities August 4, 2022

Osteopore (ASX:OSX) has announced that US-based distributor Bioplate has secured a non-exclusive agreement with MellingMedical to promote and sell its products within healthcare facilities owned or operated by the US government.

Radiopharm Theranostics announces new agreements with Lantheus and NanoMab August 4, 2022

Radiopharm Theranostics (ASX:RAD) has announced a collaboration agreement with Lantheus.

Medical Developments International announces fully underwritten capital raise August 4, 2022

Medical Developments International (ASX:MVP) has announced a fully underwritten capital raising of $30 million.

Pfizer raises offer for Australian digital health company August 4, 2022

Pfizer has significantly raised its offer for Australian digital health company ResApp Health (ASX:RAP) to a price that reflects the recent findings of an independent report.

AusBiotech 2022 programme features top industry experts August 4, 2022

AusBiotech is delighted to reveal a ‘sneak peek’ into the AusBiotech 2022 programme, which features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.

Australia’s Cell and Gene Catalyst moves ahead August 2, 2022

Australia’s Cell and Gene Catalyst will move ahead, establishing its inaugural Steering Group and opening recruitment, formally signalling the important next step in advancing cell and gene accessibility in Australia.

New study published demonstrating the utility of PromarkerD test August 2, 2022

Proteomics International Laboratories (ASX:PIQ) has announced that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease has been published in the journal PLOS ONE.

Lumos Diagnostics announces plan to close US facility August 2, 2022

Lumos Diagnostics (ASX:LDX) has announced its intention to close its facility in the US-state of Florida.

Immutep reports new data from phase 2 TACTI-002 trial August 2, 2022

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials.

Recruitment open for new study of lung disease August 2, 2022

Australian researchers are seeking volunteers aged 40 and over living with severe emphysema for a world-first study of a novel two-stage procedure to treat the lung disease.

Nominations open to recognise sector leaders July 28, 2022

Nominations for the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are now open.

Immuron provides update on FDA review of IND application July 28, 2022

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.

Most Read

New Stories

Osteopore secures US distribution agreement for government facilities

Radiopharm Theranostics announces new agreements with Lantheus and NanoMab

Medical Developments International announces fully underwritten capital raise

Pfizer raises offer for Australian digital health company

AusBiotech 2022 programme features top industry experts

Australia’s Cell and Gene Catalyst moves ahead

New study published demonstrating the utility of PromarkerD test

Sign In